📊 CADL Key Takeaways
Investment Thesis
Candel Therapeutics is a pre-revenue clinical-stage biopharmaceutical company burning significant cash with minimal commercial traction ($102K revenue) and negative operating margins exceeding -47,000%. Despite adequate liquidity buffers, the company's path to profitability remains highly uncertain with ongoing substantial losses and deteriorating cash position.
CADL Strengths
- Strong cash position of $119.7M provides 2-3 years of runway at current burn rate
- Excellent liquidity ratios (13.49x current ratio) ensure near-term solvency
- Manageable debt load relative to equity (0.89x D/E ratio) limits leverage risk
CADL Risks
- Severe unprofitability with -$38.2M net loss on near-zero revenue indicates business model execution failure
- Negative free cash flow of -$38.9M annually suggests unsustainable cash burn without milestone achievements
- Pre-commercial stage with minimal revenue generation indicates clinical development challenges and delayed commercialization timeline
- EPS of -$0.72 and negative ROE/ROA confirm value destruction for shareholders
Key Metrics to Watch
- Revenue growth trajectory and evidence of clinical trial advancement
- Monthly cash burn rate relative to cash reserves remaining
- Clinical development milestones and regulatory approval progress
- Operating cash flow improvements toward breakeven
CADL Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 13.49x current ratio provides a solid financial cushion.
CADL Profitability Ratios
CADL vs Healthcare Sector
How Candel Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CADL Balance Sheet & Liquidity
CADL 5-Year Financial Trend
5-Year Trend Summary: Candel Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.74 indicates the company is currently unprofitable.
CADL Growth Metrics (YoY)
CADL Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $31.0K | -$8.4M | $-0.29 |
| Q2 2023 | $31.0K | -$4.1M | $-0.14 |
| Q1 2023 | $31.0K | -$874.0K | $-0.03 |
| Q3 2022 | $31.0K | -$8.7M | $-0.30 |
| Q2 2022 | $31.0K | -$4.1M | $-0.14 |
| Q1 2022 | $31.0K | -$874.0K | N/A |
| Q3 2021 | $31.0K | -$2.6M | N/A |
| Q2 2021 | $31.0K | -$2.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CADL Capital Allocation
CADL SEC Filings
Access official SEC EDGAR filings for Candel Therapeutics, Inc. (CIK: 0001841387)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CADL
What is the AI rating for CADL?
Candel Therapeutics, Inc. (CADL) has an AI rating of SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CADL's key strengths?
Strong cash position of $119.7M provides 2-3 years of runway at current burn rate. Excellent liquidity ratios (13.49x current ratio) ensure near-term solvency.
What are the risks of investing in CADL?
Severe unprofitability with -$38.2M net loss on near-zero revenue indicates business model execution failure. Negative free cash flow of -$38.9M annually suggests unsustainable cash burn without milestone achievements.
What is CADL's revenue and growth?
Candel Therapeutics, Inc. reported revenue of $102.0K.
Does CADL pay dividends?
Candel Therapeutics, Inc. does not currently pay dividends.
Where can I find CADL SEC filings?
Official SEC filings for Candel Therapeutics, Inc. (CIK: 0001841387) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CADL's EPS?
Candel Therapeutics, Inc. has a diluted EPS of $-0.72.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.